Kawai Shigeto, Koishihara Yasuo, Iida Shin-ichiro, Ozaki Shuji, Matsumoto Toshio, Kosaka Masaaki, Yamada-Okabe Hisafumi
Pharmaceutical Research Department III, Chugai Pharmaceutical Co. Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan.
Leuk Res. 2006 Aug;30(8):949-56. doi: 10.1016/j.leukres.2005.11.023. Epub 2006 Feb 13.
A humanized monoclonal antibody (mAb) against HM1.24 (AHM) caused antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma (MM) cells. Here, we constructed a conventional non-radioisotope method that quantifies the amount of HM1.24 using fluorescein-labeled AHM. More than 10(4) molecules/cell of HM1.24 were detected in 12 out of 14 patients' MM cells, and a linear correlation was found between ADCC by AHM and the amounts of HM1.24. Thus, AHM is likely to be more efficacious against MM cells with high levels of HM1.24. This conventional non-RI method to quantify HM1.24 will be useful to select patients most likely to respond to AHM.
一种针对HM1.24的人源化单克隆抗体（mAb，即AHM）可引发针对多发性骨髓瘤（MM）细胞的抗体依赖性细胞毒性（ADCC）。在此，我们构建了一种传统的非放射性同位素方法，该方法使用荧光素标记的AHM来定量HM1.24的量。在14例患者的MM细胞中，有12例检测到每细胞超过10⁴个分子的HM1.24，并且发现AHM介导的ADCC与HM1.24的量之间存在线性相关性。因此，AHM可能对高水平表达HM1.24的MM细胞更有效。这种用于定量HM1.24的传统非放射性同位素方法将有助于选择最有可能对AHM产生反应的患者。
